Mounjaro is a brand-name prescription medication containing tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is approved for improving blood sugar control in adults with type 2 diabetes and has also shown significant efficacy in weight management. It works by activating both GIP and GLP-1 receptors, leading to enhanced insulin secretion, reduced glucagon secretion, delayed gastric emptying, and decreased appetite.
Ompic is a mimic of those and Monero and things like that.
""Dr. Michael Snyder discussed Mounjaro as a more potent GLP-1 agonist that he personally uses for managing his type 2 diabetes. He shared his experience of switching to Mounjaro due to nausea from a previous drug and its significant impact on lowering his hemoglobin A1C and causing weight loss, including the 'evaporation' of fat as seen in his body MRIs."